China’s medicine regulator, the National Medical Products Administration (NMPA), has ordered a halt on the import, sale, and use of a drug made by India’s Sun Pharmaceutical Industries. The banned drug is rivastigmine hydrogen tartrate capsules, used to treat dementia linked to Alzheimer’s disease. The order came after a recent remote inspection found problems in Sun Pharma’s production process. These issues included failure to prevent contamination and poor performance by the quality management department. A Sun Pharma spokesperson has not responded to requests for comment. This is not the first time Sun Pharma faced trouble. In 2024, the US Food and Drug Administration issued a warning letter about major violations of manufacturing rules at the same Indian site. Rivastigmine capsules are used in China as a treatment for dementia, according to studies. The ban was announced on January 26, 2026.